Clinical Study

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study To Assess The Efficacy And Safety Of Oral Bps-314D-Mr Added-On To Treprostinil, Inhaled (Tyvaso®) In Subjects With Pulmonary Arterial Hypertension

Posted Date: Apr 23, 2018

  • Investigator: Jean Elwing
  • Specialties: Lung Disease, Pulmonary Diseases
  • Type of Study: Drug

The purpose of this study is to compare the effect of an oral (by mouth) prostanoid to placebo, when both are used with inhaled Tyvaso. The study will also evaluate the safety of this prostanoid. This study will also keep track of changes in your exercise ability to determine if your PAH worsens. The oral prostanoid is an investigational drug called Beraprost Sodium-314d-Modified Release (BPS-314d-MR). An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA).

Criteria:

You Are Being Asked To Take Part In This Research Study Because You Have Pulmonary Arterial Hypertension (Pah), Which Means That You Have High Blood Pressure In Your Lungs. In Addition, Your Doctors Have Determined That Based On Your Current Pah Condition, You May Be A Likely Candidate For This Study.

Keywords:

Lung Disease, Pah, Pulmonary, Pulmonary Arterial Hypertension , Shortness Of Breath

For More Information:

Melissa Banuelos
(513) 558-2187
banuelma@ucmail.uc.edu